Anthony Tjan - Equillium Independent Director
| EQ Stock | USD 1.72 0.07 4.24% |
Director
Mr. Anthony Tjan is an Independent Director of EQ Inc. Mr. Tjan is Chief Executive Officer and Managing Partner of The Cue Ball Group of Companies, a private holding company and VC firm focused on early growth equity investments in the information, Internet media, and specialty consumer industries. Until early 2005, he served as Senior Partner with The Parthenon Group, a leading strategy consulting firm where he remains Vice Chairman. In 1996 he founded the pioneering Internet and technology consulting company ZEFER, now Niteo Partners a division of NEC. He began his professional career with McKinsey Company. Additionally, Mr. Tjan is one of the World Economic Forums Global Leaders for Tomorrow and sits on the Boards andor Advisory Boards of Scroll Motion, Shake Up, Epic Burger, Knovel Corporationrationration, MiniLuxe, From the Top Inc. and the Editorial Advisory Board of MIT Technology Review. He also serves on the faculty of Harvard Business School as an Entrepreneur in Residence and is the New York Times bestselling author of Heart, Smarts, Guts and Luck since 2005.
| Tenure | 19 years |
| Professional Marks | MBA |
| Address | 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 |
| Phone | 858 240 1200 |
| Web | https://www.equilliumbio.com |
Equillium Management Efficiency
The company has Return on Asset (ROA) of (0.1408) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1408. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.4892) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/24/2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Equillium's Total Current Liabilities is relatively stable compared to the past year. As of 04/24/2024, Liabilities And Stockholders Equity is likely to grow to about 67.5 M, while Non Current Liabilities Total is likely to drop slightly above 364.8 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Eliahu Shohet | Bolt Biotherapeutics | 56 | |
| Will Feest | AN2 Therapeutics | N/A | |
| Christos Richards | Coherus BioSciences | 59 | |
| Tamar Kfir | Bolt Biotherapeutics | 47 | |
| Mario Traverso | Bolt Biotherapeutics | N/A | |
| Cynthia Smith | Spero Therapeutics | 49 | |
| John Pottage | Spero Therapeutics | N/A | |
| Guillermo Gabella | Bolt Biotherapeutics | N/A | |
| Peter Kiener | Cue Biopharma | 63 | |
| Iwan Harianto | Bolt Biotherapeutics | 62 | |
| James Blair | aTyr Pharma | 78 | |
| Barry Simon | Cue Biopharma | 53 | |
| Svetlana Lucas | aTyr Pharma | N/A | |
| JeanFranois Formela | Spero Therapeutics | 61 | |
| Lewis Hay | AN2 Therapeutics | 60 | |
| Frank Thomas | Spero Therapeutics | 47 | |
| JeanFrancois Formela | Spero Therapeutics | 60 | |
| Efrat Makov | Bolt Biotherapeutics | 44 | |
| Anibal Bernardo | Bolt Biotherapeutics | N/A | |
| Janto Pangestu | Bolt Biotherapeutics | 59 | |
| Mats Wahlstrom | Coherus BioSciences | 64 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.14 |
Equillium Leadership Team
Elected by the shareholders, the Equillium's board of directors comprises two types of representatives: Equillium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Equillium. The board's role is to monitor Equillium's management team and ensure that shareholders' interests are well served. Equillium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Equillium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Fisher, Independent Director | ||
| Jason Keyes, Chief Officer | ||
| Penny Tom, Principal Officer | ||
| Anthony Tjan, Independent Director | ||
| Daniel Bradbury, Chairman of the Board, CEO | ||
| Joel Rothman, Chief Officer | ||
| Krishna Polu, Chief Medical Officer | ||
| Marc Lavine, Independent Director | ||
| Charles McDermott, Independent Director | ||
| Bruce Steel, President Chief Business Officer and Director | ||
| PMP MBA, Senior COO | ||
| Matthew Ritter, Senior Development | ||
| Maple MD, Chief Officer | ||
| Krishna MD, Consultant | ||
| Geoffrey Rotstein, President CEO, Director | ||
| Bruce CFA, President, CoFounder | ||
| Bala Manian, Independent Director | ||
| Michael Moore, Vice Communications | ||
| Dilshan Kathriarachchi, CTO | ||
| Stephen Connelly, Chief Scientific Officer, Director | ||
| Peter Kanniah, CFO, Secretary | ||
| Martha Demski, Independent Director | ||
| Mark Pruzanski, Independent Director | ||
| Vernon Lobo, Independent Chairman of the Board |
Equillium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Equillium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | 18.13 M | ||||
| Shares Outstanding | 35.25 M | ||||
| Shares Owned By Insiders | 36.42 % | ||||
| Shares Owned By Institutions | 21.76 % | ||||
| Number Of Shares Shorted | 394.47 K | ||||
| Price To Earning | (6.70) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Equillium in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Equillium's short interest history, or implied volatility extrapolated from Equillium options trading.
Pair Trading with Equillium
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Equillium position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will appreciate offsetting losses from the drop in the long position's value.Moving against Equillium Stock
| 0.52 | EVO | Evotec SE ADR Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Equillium could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Equillium when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Equillium - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Equillium to buy it.
The correlation of Equillium is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Equillium moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Equillium moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Equillium can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Equillium Stock analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Equillium's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Equillium. If investors know Equillium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Equillium listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Revenue Per Share 1.039 | Quarterly Revenue Growth (0.42) | Return On Assets (0.14) | Return On Equity (0.49) |
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine if Equillium is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.